Antituberculosis drug resistance acquired during treatment: An analysis of cases reported in California, 1994-2006

Clinical Infectious Diseases

Volumn 56, Issue 6, 2013, Pages 761-769

  Porco, Travis C ^a,b   Oh, Peter ^c   Flood, Jennifer M ^c  

^a FI Proctor Foundation   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

acquired drug resistance; isoniazid; multidrug resistance; rifampicin; tuberculosis

Indexed keywords

ISONIAZID; RIFAMPICIN;

ARTICLE; DISEASE REGISTRY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; UNITED STATES;

ADULT; AGED; ANTITUBERCULAR AGENTS; CALIFORNIA; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; TUBERCULOSIS, PULMONARY;

EID: 84874777764     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis989     Document Type: Article

References (33)

1. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva, Switzerland: World Health Organization, 2010.
2. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2009. Atlanta, GA: US Department of Health and Human Services, CDC, 2010.
3. Westenhouse J, Allen J, Johnson L, Kanowitz S, Waldow K. California Department of Public Health. Report on tuberculosis in California, 2009. 2010.
4. Francis J. Curry National Tuberculosis Center. Drug-resistant tuberculosis: a survival guide for clinicians. 2nd ed. San Francisco, CA: Francis J. Curry National Tuberculosis Center and California Department of Public Health, 2008.
5. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328:527-32.
6. Granich RM, Oh P, Lewis B, Porco TC, Flood J. Multidrug resistance among persons with tuberculosis in California, 1994-2003. JAMA 2005; 293:2732-9.
7. Gerberding J. Extensively drug-resistant TB: CDC's public health response. Committee on Foreign Affairs, Subcommittee on Africa and Global Health, 2007. http://www.hhs.gov/asl/testify/2007/03/t20070321c.html. Accessed 18 December 2012.
8. Banerjee R, Allen J, Westenhouse J, et al. Extensively drug-resistant tuberculosis in California, 1993-2006. Clin Infect Dis 2008; 47:450-7.
9. Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 2002; 46:267-74.
10. Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. New Engl J Med 1993; 328:1137-44.
11. Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis 2003; 3:13-21.
12. Van Rie A, Warren R, Richardson M, et al. Classification of drug-resistant tuberculosis in an epidemic area. Lancet 2000; 356:22-5.
13. El Sahly HM, Teeter LD, Pawlak RR, Musser JM, Graviss EA. Drugresistant tuberculosis: a disease of target populations in Houston, Texas. J Infect 2006; 53:5-11.
14. Bradford WZ, Martin JN, Reingold AL, Schecter GF, Hopewell PC, Small PM. The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA. Lancet 1996; 348:928-31.
15. Moore M, Onorato IM, McCray E, Castro KG. Trends in drug-resistant tuberculosis in the United States, 1993-1996. JAMA 1997; 278:833-7.
16. Tango T. A test for spatial disease clustering adjusted for multiple testing. Stat Med 2000; 19:191-204.
17. Conaty SJ, Hayward AC, Story A, Glynn JR, Drobniewski FA, Watson JM. Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance. Epidemiol Infect 2004; 132:1099-108.
18. Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and metaanalysis. Ann Intern Med 2008; 149:123-34.
19. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2:10-5.
20. Quy HT, Lan NT, Borgdorff MW, et al. Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int J Tuberc Lung Dis 2003; 7:631-6.
21. Yoshiyama T, Yanai H, Rhiengtong D, et al. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Int J Tuberc Lung Dis 2004; 8:31-8.
22. Lutfey M, Della-Latta P, Kapur V, et al. Independent origin of monorifampin- resistant Mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med 1996; 153:837-40.
23. Ridzon R, Whitney CG, McKenna MT, et al. Risk factors for rifampin monoresistant tuberculosis. Am J Respir Crit Care Med 1998; 157:1881-4.
24. Hlavsa MC, Moonan PK, Cowan LS, et al. Human tuberculosis due to Mycobacterium bovis in the United States, 1995-2005. Clin Infect Dis 2008; 47:168-75.
25. Liaw YS, Hsueh PR, Yu CJ, Wang SK, Yang PC, Luh KT. Drug resistance pattern of Mycobacterium tuberculosis in a university hospital in Taiwan, 1998-2002. J Formos Med Assoc 2004; 103:671-7.
26. Fujino T, Hasegawa N, Satou R, Komatsu H, Kawada K. Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results. Kekkaku 1998; 73:471-6.
27. Jasmer RM, Seaman CB, Gonzalez LC, Kawamura LM, Osmond DH, Daley CL. Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med 2004; 170:561-6.
28. Munsiff SS, Joseph S, Ebrahimzadeh A, Frieden TR. Rifampin-monoresistant tuberculosis in New York City, 1993-1994. Clin Infect Dis 1997; 25:1465-7.
29. Han LL, Sloutsky A, Canales R, et al. Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly observed empiric retreatment with standardized regimens. Int J Tuberc Lung Dis 2005; 9:818-21.
30. Sonnenberg P, Murray J, Shearer S, Glynn JR, Kambashi B, Godfrey-Faussett P. Tuberculosis treatment failure and drug resistance: same strain or reinfection? Trans R Soc Trop Med Hyg 2000; 94: 603-7.
31. Heifets LB, Cangelosi GA. Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis 1999; 3:564-81.
32. Marks SM, Armstrong L, Flood J, et al. Treatment practices, outcomes, and cost of multidrug-resistant and extensively drug resistant tuberculosis in the United States: preliminary results [abstract]. Am J Respir Crit Care Med 2012; 185:A3308.
33. Holmquist L, Russo CA, Elixhauser A. Tuberculosis stays in U.S. hospitals, HCUP Statistical Brief #60, 2008. Rockville, MD: Agency for Healthcare Research and Quality.